Search Result

Isoforms Recommended:	IKZF1

Results for "

IKZF1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Btk (1) c-Myc (1) Casein Kinase (3) CDK (3) Fluorescent Dye (1) IKZF Family (6) Interleukin Related (1) Isotope-Labeled Compounds (2) Ligands for E3 Ligase (8) MAP4K (1) Molecular Glues (12) Phosphodiesterase (PDE) (1) PROTACs (8) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (9)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111594

Homo-PROTAC cereblon degrader 1 1 Publications Verification	PROTACs	Cancer
Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient Cereblon (CRBN) degrader with only minimal effects on *IKZF1* and *IKZF3* ^[1].

HY-A0003

Lenalidomide Maximum Cited Publications 40 Publications Verification CC-5013	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003B

Lenalidomide hemihydrate Maximum Cited Publications 40 Publications Verification CC-5013 hemihydrate	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-136262

CRBN-6-5-5-VHL	PROTACs	Cancer
CRBN-6-5-5-VHL is a potent and selective von Hippel-Lindau-based cereblon (CRBN) degrader with a DC₅₀ value of 1.5 nM. CRBN-6-5-5-VHL has almost no effect on the degradation of the neo-substrates IKZF1 and IKZF3 ^[1].

HY-RS06665

IKZF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IKZF1 Human Pre-designed siRNA Set A contains three designed siRNAs for IKZF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IKZF1 Human Pre-designed siRNA Set A IKZF1 Human Pre-designed siRNA Set A

HY-160531

IKZF1-degrader-1	Molecular Glues IKZF Family	Cancer
IKZF1-degrader-1 (Compound 9-B) is a *IKZF1* molecular glue degrader with the DC₅₀ value of 0.134 nM. IKZF1-degrader-1 can be used to degrader tumors ^[1].

HY-160533

IKZF1-degrader-2	Molecular Glues IKZF Family	Cancer
IKZF1-degrader-2 (Compound 3) is an *IKZF1* molecular glues degrader. IKZF1-degrader-2 has anticancer activity and low toxicity ^[1].

HY-162014

WDR5 degrader-1	PROTACs	Cancer
WDR5 degrader-1 (compound 25) is a cereblon (CRBN)-recruiting WDR5 degrader. WDR5 degrader-1 selectively degraded WDR5 over the CRBN neo-substrate IKZF1 ^[1].

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligands for E3 Ligase Molecular Glues	Inflammation/Immunology Cancer
Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-143435

AG6033	Apoptosis	Cancer
AG6033 is a potential novel CRBN modulator. AG6033 suppresses various tumor cells by modulating the interactions between CRBN and various antitumor target proteins. AG6033 can cause GSPT1 and IKZF1 degradation. AG6033 induces CRBN-dependent cytotoxic effect ^[1].

HY-145319

FPFT-2216	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Inflammation/Immunology Cancer
FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease ^[1] .

HY-145776

ALV1	Molecular Glues Ligands for E3 Ligase IKZF Family Interleukin Related	Inflammation/Immunology Cancer
ALV1 is a molecular glue degrader for Ikaros (IKZF1) and Helios (IKZF2), with DC₅₀ values of 2.5 nM and 10.3 nM, respectively. ALV1 binds CRBN with an IC₅₀ of 0.55 µM. ALV1 induces CRBN-Helios dimerization. ALV1 can be used to study the properties and functions of T_reg cells ^[1].

HY-A0003R

Lenalidomide (Standard)	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide (Standard) is the analytical standard of Lenalidomide. This product is intended for research and analytical applications. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-168614

MGD-4	IKZF Family	Cancer
MGD-4 is an orally active, Cereblon (CRBN)-dependent IKAROS protein degrader that degrades *IKZF1* (DC₅₀=67.2 nM), *IKZF2* (DC₅₀=918.2 nM), and *IKZF3* (DC₅₀=95.8 nM) in a dose-dependent manner. MGD-4 effectively inhibits the growth of multiple myeloma ^[1].

HY-A0003S2

Lenalidomide-13C5,15N CC-5013-¹³C₅,¹⁵N	Ligands for E3 Ligase Apoptosis Molecular Glues Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-123714

TL4-12	MAP4K Apoptosis	Inflammation/Immunology Cancer
TL4-12 is a selective MAP4K2/GCK inhibitor, dose-dependently downregulates IKZF1 and BCL-6 and leads to MM cell proliferation inhibition (IC₅₀=37 nM) accompanied by induction of apoptosis. TL4-12 can be used to overcome immunomodulatory agent resistance in multiple myeloma (MM) ^[1].

HY-W760183

EM12-SO2F	Fluorescent Dye	Cancer
EM12-SO2F is a powerful covalent inhibitor of CRBN through binding at His353. EM12-SO2F is a useful chemical probe to investigate the CRBN. EM12-SO2F inhibits the degradation of *IKZF1* by lenalidomide (HY-A0003) in MOLT4 cells ^[1]

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity ^[1].

HY-168615

MGD-28	IKZF Family Casein Kinase	Cancer
MGD-28 is a potent, orally active, Cereblon (CRBN)-dependent IKAROS protein degrader that degrades *IKZF1* (DC₅₀=3.8 nM), *IKZF2* (DC₅₀=56.3 nM), and *IKZF3* (DC₅₀=7.1 nM) in a dose-dependent manner. In addition, MGD-4 also degrades *CK1α* (DC₅₀=7.8 nM). MGD-28 has antiproliferative activity and can be used in multiple myeloma research ^[1].

HY-136252

BSJ-04-132	PROTACs CDK	Cancer
BSJ-04-132 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC₅₀s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity ^[1].

HY-136250A

BSJ-03-204 triTFA	PROTACs CDK	Cancer
BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity ^[1].

HY-A0003S

Lenalidomide-d5 CC-5013-d₅	Isotope-Labeled Compounds Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-148837

PROTAC c-Myc degrader-1	PROTACs c-Myc Casein Kinase	Infection Cardiovascular Disease Cancer
PROTAC c-Myc degrader-1 (Compound A153) is a multiple target protein degrader (PROTAC). PROTAC c-Myc degrader-1 effective degrades c-MYC, *CK1α, GSPT1* and *IKZF1/2/3* proteins in a variety of tumor cells. PROTAC c-Myc degrader-1 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection (Pink: c-Myc ligand (HY-168685); Blue: E3 ligase ligand (HY-W093472); Black: linker (HY-W015808)) ^[1].

HY-153220

NX-2127	PROTACs Btk	Cancer
NX-2127 (compound 28) is an orally active PROTAC deggrader, targeting to Bruton’s Tyrosine Kinase (Btk) . NX-2127 inhibits proliferation of BTK ^C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells ^[1] . NX-2127 is composed of PROTAC target protein ligand (red part) BTK ligand 10 (HY-168302), E3 ligase ligand (blue part) Thalidomide 5-fluoride (HY-W087383) and PROTAC Linker (black part) (S)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168303). Among which, the conjugate of E3 ubiquitin ligase ligand + Linker compose of Thalidomide-pyrrolidine-C-piperidine-Ph-NH2 (HY-168304).

HY-170518

IKZF-IN-1	IKZF Family	Infection Cancer
IKZF-IN-1 (Compound I) is the molecular glue, that degrades ikaros zinc finger family (IKZF) IKZF 1/2/3/4, and can be used as an immunomodulator in research of cancer and viral infections ^[1].

HY-144841

Cemsidomide CFT7455	Molecular Glues	Cancer
Cemsidomide (CFT7455) is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity ^[1]. Cemsidomide has a GI₅₀ of 0.05 nM for NCIH929.1 cells.

HY-130800

Eragidomide 2 Publications Verification CC-90009	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 ^CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation ^[1] .

Cat. No.	Product Name	Chemical Structure

HY-A0003S

Lenalidomide-d5
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-A0003S2

Lenalidomide-13C5,15N
Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

Lenalidomide-13C5,15N

Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81282

	Ikaros Antibody (YA987) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; IKZF1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	WB, IP	Human
	Ikaros Antibody (YA987) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA987), targeting Ikaros, with a predicted molecular weight of 58 kDa (observed band size: 58 kDa). Ikaros Antibody (YA987) can be used for WB, IP experiment in human background.

HY-P81282A

	Ikaros Antibody (YA988) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; IKZF1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	IHC-P	Human
	Ikaros Antibody (YA988) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA988), targeting Ikaros. Ikaros Antibody (YA988) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

IKZF1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
IKZF1 Human Pre-designed siRNA Set A contains three designed siRNAs for IKZF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: